title: Effect of obesity on clinical presentation and response to treatment in asthma.
abstract: Obesity is a risk factor for being diagnosed with asthma, but there is conflicting evidence on whether obesity is a risk factor for lung function abnormalities characteristic of asthma. We studied a cohort of 488 subjects, 47% of whom were obese. Obese and non-obese subjects with asthma had similar airflow limitation and bronchodilator responsiveness, but obese participants had increased sleep disturbance and gastroesophageal reflux disease, higher cytokine levels, and a trend towards increased exacerbations when treated with theophylline. Obese and non-obese asthmatics have similar lung function abnormalities, but comorbidities and altered responses to medications may significantly affect asthma control in obese people.
authors.affiliation: University of Vermont, Burlington, VT 05401, USA. anne.dixon@uvm.edu
authors.forename: Anne E
authors.initials: AE
authors.lastname: Dixon
authors.forename: David M
authors.initials: DM
authors.lastname: Shade
authors.forename: Rubin I
authors.initials: RI
authors.lastname: Cohen
authors.forename: Gwen S
authors.initials: GS
authors.lastname: Skloot
authors.forename: Janet T
authors.initials: JT
authors.lastname: Holbrook
authors.forename: Lewis J
authors.initials: LJ
authors.lastname: Smith
authors.forename: John J
authors.initials: JJ
authors.lastname: Lima
authors.forename: Hooman
authors.initials: H
authors.lastname: Allayee
authors.forename: Charles G
authors.initials: CG
authors.lastname: Irvin
authors.forename: Robert A
authors.initials: RA
authors.lastname: Wise
mesh_terms: D000085:Acetates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D001993:Bronchodilator Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003521:Cyclopropanes; D016207:Cytokines / Q000097:blood; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000453:epidemiology; D011804:Quinolines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012307:Risk Factors; D012893:Sleep Wake Disorders / Q000175:diagnosis / Q000453:epidemiology; D013440:Sulfides; D013806:Theophylline / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D016207:Cytokines; D011804:Quinolines; D013440:Sulfides; D013806:Theophylline; C093875:montelukast